Tuesday, Human Genome Sciences, Inc. (HGSI) said, as expected, it received a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration, or FDA, regarding the company's Biologics License Application, or BLA, for 900-mcg ZALBIN dosed every two weeks for treating chronic hepatitis C.
HGS and Novartis decided not to develop ZALBIN further.
HGS, Human Genome Sciences and ZALBIN are trademarks of Human Genome Sciences, Inc.
For comments and feedback: editorial@rttnews.com